Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 8/20 | 0.35 |
| ▸ | RAB9A | P51151 | 8/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | CCR3 | P51677 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23638517 | 0.83 | NPC1 (0.46) | PPARGNPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL30699261 | 0.82 | MAPT (0.43) | PPARGGRM2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23638500 | 0.82 | MAPT (0.43) | PPARGGRM2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24330834 | 0.80 | MAPT (0.41) | PPARGNPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL3397691 | 0.78 | RAB9A (0.55) | NPC1RAB9ASMN1; SMN2GAALMNA | |
| SCHEMBL2119107 | 0.76 | CHRM4 (0.38) | KDM4E | |
| SCHEMBL1259875 | 0.75 | RHEB (0.40) | GRM2NPC1RAB9AGAACCR3 | |
| SCHEMBL23638501 | 0.73 | IRAK4 (0.38) | PPARG | |
| SCHEMBL15111988 | 0.68 | MEN1 (0.43) | NPC1RAB9ASMN1; SMN2GAAUSP2 | |
| SCHEMBL31473593 | 0.67 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100310675-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-7767672-B2 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-03 | — | — | US | disclosed |
| US-20070259869-A1 | Aminopyrimidines useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310675-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | ABL1, PRKDC, MAP3K5 | PPARG 3620/4885GRM2 3036/4885NPC1 3398/4885 |
| US-20070259869-A1 | Aminopyrimidines useful as kinase inhibitors | ABL1, PRKDC, MAP3K5 | PPARG 3620/4885GRM2 3036/4885NPC1 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.